MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 23 June 2025: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer of Alterity, will participate in a Fireside Chat hosted by MST Access on Wednesday, 25 June 2025 in Australia / Tuesday, 24 June 2025 in the United States. Dr. Stamler will provide a corporate update with a focus on the progress made on the ATH434 development program in Multiple System Atrophy since the Company released positive Phase 2 data in January.
Webcast details
AUSTRALIA PARTICIPANTS:
Date: Wednesday, 25 June 2025
Time: 9:00 a.m. AEST (Sydney/Melbourne)
UNITED STATES PARTICIPANTS:
Date: Tuesday, 24 June 2025
Time: 4:00 p.m. Pacific Time
7:00 p.m. Eastern Time
Register for the Zoom webcast:
https://mstfinancial-au.zoom.us/webinar/register/WN_4ubiApljT2yBv9q-wbzzUQ#/registration
Registration is required and dial in details will be sent directly upon registration.
The webcast recording will be available on the Events and Presentation page of the Company's website here.
About Alterity Therapeutics Limited
Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. The Company is initially focused on developing disease modifying therapies in Parkinson's disease and related disorders. Alterity recently reported positive data for its lead asset, ATH434, in a Phase 2 clinical trial in participants with Multiple System Atrophy (MSA), a rare and rapidly progressive Parkinsonian disorder. ATH434 is also being evaluated in a Phase 2 clinical trial in advanced MSA. In addition, Alterity has a broad drug discovery platform generating patentable chemical compounds to treat the underlying pathology of neurological diseases. The Company is based in Melbourne, Australia, and San Francisco, California, USA. For further information please visit the Company's website at https://www.alteritytherapeutics.com.
Authorisation & Additional information
This announcement was authorized by David Stamler, CEO of Alterity Therapeutics Limited.
June 5, 2017August 16, 2022
July 17, 2013August 16, 2022
February 10, 2025March 10, 2025
Your email address will not be published.Required fields are marked *
Save my name, email, and website in this browser for the next time I comment.
Δ
Attachments
- Original document
- Permalink
Disclaimer
Alterity Therapeutics Ltd. published this content on June 23, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on June 23, 2025 at 02:20 UTC.
